Elias Kotteas1, Muhammad Wasif Saif2, Konstantinos Syrigos3,4. 1. Oncology Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Athens University School of Medicine, 152 Mesogeion Avenue, Athens, Greece. ilkotteas@hotmail.com. 2. Section of GI and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA. 3. Oncology Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Athens University School of Medicine, 152 Mesogeion Avenue, Athens, Greece. 4. Yale School of Medicine, New Haven, CT, USA.
Abstract
INTRODUCTION: Pancreatic cancer is among the most lethal malignancies resistant to conventional therapies. The vast majority of patients is diagnosed with advanced/metastatic disease and consequently has grim prognosis. Despite the available options with nab-paclitaxel and gemcitabine or 5-fluorouracil/leucovorin/oxaliplatin, chemotherapy offers a modest survival benefit. Targeted therapy in combination with chemotherapy has not shown significant improvement in treatment outcomes. The urgent need for new therapies has turned the spotlights on immunotherapy. Immunotherapy in pancreatic cancer recruits and activates T cells which recognize tumor-specific antigens. RESULTS: Preclinical models have demonstrated that chemotherapy or targeted therapy works synergistically with immunotherapy. A growing body of evidence has already been gathered regarding the efficacy of checkpoint inhibitors, vaccines, adoptive T cell therapy, monoclonal antibodies, and cytokines in patients with pancreatic cancer. CONCLUSIONS: Many ongoing trials are aiming to identify treatments which could combine efficacy with limited toxicity. In this article, we review the available data concerning multiple aspects of immunotherapy in pancreatic cancer.
INTRODUCTION: Pancreatic cancer is among the most lethal malignancies resistant to conventional therapies. The vast majority of patients is diagnosed with advanced/metastatic disease and consequently has grim prognosis. Despite the available options with nab-paclitaxel and gemcitabine or 5-fluorouracil/leucovorin/oxaliplatin, chemotherapy offers a modest survival benefit. Targeted therapy in combination with chemotherapy has not shown significant improvement in treatment outcomes. The urgent need for new therapies has turned the spotlights on immunotherapy. Immunotherapy in pancreatic cancer recruits and activates T cells which recognize tumor-specific antigens. RESULTS: Preclinical models have demonstrated that chemotherapy or targeted therapy works synergistically with immunotherapy. A growing body of evidence has already been gathered regarding the efficacy of checkpoint inhibitors, vaccines, adoptive T cell therapy, monoclonal antibodies, and cytokines in patients with pancreatic cancer. CONCLUSIONS: Many ongoing trials are aiming to identify treatments which could combine efficacy with limited toxicity. In this article, we review the available data concerning multiple aspects of immunotherapy in pancreatic cancer.
Authors: Seza A Gulec; Steven J Cohen; Kenneth L Pennington; Lionel S Zuckier; Ralph J Hauke; Heather Horne; William A Wegener; Nick Teoh; David V Gold; Robert M Sharkey; David M Goldenberg Journal: Clin Cancer Res Date: 2011-04-28 Impact factor: 12.531
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: S L Bernhardt; M K Gjertsen; S Trachsel; M Møller; J A Eriksen; M Meo; T Buanes; G Gaudernack Journal: Br J Cancer Date: 2006-10-24 Impact factor: 7.640
Authors: Howard L Kaufman; Seunghee Kim-Schulze; Kelledy Manson; Gail DeRaffele; Josephine Mitcham; Kang Seok Seo; Dae Won Kim; John Marshall Journal: J Transl Med Date: 2007-11-26 Impact factor: 5.531
Authors: Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee Journal: Clin Cancer Res Date: 2017-04-01 Impact factor: 12.531
Authors: Ezekiel Maloney; Tanya Khokhlova; Venu G Pillarisetty; George R Schade; Elizabeth A Repasky; Yak-Nam Wang; Lorenzo Giuliani; Matteo Primavera; Joo Ha Hwang Journal: Int Rev Immunol Date: 2017-09-29 Impact factor: 5.311
Authors: Daniel R Principe; Brian DeCant; Andrew M Diaz; Riley J Mangan; Rosa Hwang; Andrew Lowy; Brandon B Shetuni; Bharath K Sreekumar; Chuhan Chung; David J Bentrem; Hidayatullah G Munshi; Barbara Jung; Paul J Grippo; Faraz Bishehsari Journal: Oncotarget Date: 2016-05-10